AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27720403
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg calcitriol
Trial: 27720403
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium carbonate + 25 μg calcitriol
Trial: 22886138
Drug: Polidocanol (POL)
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polidocanol (POL) micro-foam injection
Trial: 22886138
Drug: Laser after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser after POL injection
Trial: 15265408
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg (group RE, n = 15)
Trial: 10421125
Drug: Enflurane administration
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enflurane administration (0.5% to 2%) for 5 minutes
Trial: 10421125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no enflurane administration)
Trial: 7554976
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of contraceptive pill for 21 days with a seven-day interruption (intermittent use)
Trial: 7554976
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of contraceptive pill without interruption (continuous use)
Trial: 6158370
Drug: Vinblastine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 0.4 mg/kg every three weeks for four courses
Trial: 6158370
Drug: Vinblastine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 0.3 mg/kg every three weeks for four courses
Trial: 6158370
Drug: Vinblastine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every three weeks for four courses
Trial: 6158370
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months
Trial: 28115877
Drug: Intrathecal Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Morphine (Group M)
Trial: 22190273
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (1,000 mg calcium carbonate plus 400 IU vitamin D(3) daily)
Trial: 17340636
Drug: S1 (gadolinium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1 (gadolinium as oral tagging agent and a gadolinium-water mixture for rectal filling)
Trial: 17340636
Drug: S2 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S2 (oral barium and water rectally)
Trial: 17340636
Drug: S3 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S3 (oral barium and air rectally)
Trial: 16336763
Drug: Two protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two protease inhibitors (saquinavir + nelfinavir)
Trial: 16336763
Drug: One protease
RxNorm normalized name: Sea anemone protease A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One protease inhibitor (saquinavir soft gel capsule)
Trial: 18205965
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (CBT)
Trial: 14626395
Drug: Preincisional periportal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional periportal infiltration with 20 mL of ropivacaine (10 mg/mL)
Trial: 10711915
Drug: Nortriptyline maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline maintenance therapy (plasma levels 60-150 ng/mL) for up to 2 years
Trial: 9352864
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.25 IU/kg body wt)
Trial: 31442298
Drug: Ticagrelor-monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor-monotherapy
Trial: 22886852
Drug: Atropine/scopolamine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine/scopolamine mixture at 12.10/9.50 µg kg(‐1) body mass (BM)
Trial: 22886852
Drug: Atropine/scopolamine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine/scopolamine mixture at 0.37/0.29 and 1.22/0.95 µg kg(‐1) BM
Trial: 22886852
Drug: Atropine/scopolamine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine/scopolamine mixture at 0.12/0.10 µg kg(‐1) BM
Trial: 22886852
Drug: Atropine/scopolamine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine/scopolamine mixture (various doses)
Trial: 21982669
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein ≥6.6 mg/L
Trial: 16343498
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin infusion 20 units
Trial: 8621132
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/d for 6 weeks)
Trial: 6131624
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg orally
Trial: 3977064
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 30 ml orally
Trial: 29961998
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 to 4 mg
Trial: 25755685
Drug: 13.3 mg/24
RxNorm normalized name: Exelon, 13.3 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.3 mg/24 h rivastigmine patch
Trial: 23924050
Drug: 4.6 mg/24
RxNorm normalized name: Exelon, 4.6 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.6 mg/24 h rivastigmine patch
Trial: 24257390
Drug: Cisatracurium +
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium + Albuterol
Trial: 24257390
Drug: Rocuronium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium + Albuterol
Trial: 15610805
Drug: Oral oxytetracycline
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxytetracycline plus topical placebo
Trial: 15610805
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline plus topical placebo
Trial: 15610805
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide plus oral placebo
Trial: 15610805
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin and benzoyl peroxide in a combined formulation plus oral placebo
Trial: 15610805
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin and benzoyl peroxide separately plus oral placebo
Trial: 15610805
Drug: Erythromycin and
RxNorm normalized name: Erythromycin and zinc only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin and benzoyl peroxide separately versus combined formulation
Trial: 15610805
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide versus combined formulation
Trial: 12177686
Drug: Galantamine 16
RxNorm normalized name: galantamine 16 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 16 mg/day
Trial: 9205760
Drug: Ebrotidine (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (150, 300, 400, 500, 600, 800 mg)
Trial: 31917765
Drug: Double low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Double low-dose group (n = 35)
Trial: 31917765
Drug: Standard-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose group (n = 32)
Trial: 28787186
Drug: Tralokinumab 400
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab 400 mg
Trial: 28787186
Drug: Tralokinumab 800
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab 800 mg
Trial: 27391985
Drug: Inpatient general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient general psychiatric treatment
Trial: 18931495
Drug: Erosion +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erosion + caries (EC) - cola drink 3 times/day + sucrose solution 8 times/day with plaque
Trial: 18931495
Drug: Caries only
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caries only (CO) - sucrose solution 8 times/day with plaque
Trial: 14744417
Drug: Freshly prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freshly prepared patches
Trial: 14744417
Drug: Previously prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previously prepared and stored patches
Trial: 6403546
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliomyelitis vaccine prepared from monkey kidney cells
Trial: 6403546
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliomyelitis vaccine prepared from human diploid cells (MRC5)
Trial: 31576697
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus durvalumab and tremelimumab
Trial: 31576697
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus durvalumab
Trial: 1442907
Drug: Localized cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localized cold therapy to the cesarean section incision
Trial: 22729756
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy (KT) using oscillating beds (TryaDyne Proventa, KCI)
Trial: 18369092
Drug: Low-Fructose (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Fructose (0.3 g/min)
Trial: 18369092
Drug: Medium-Fructose (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-Fructose (0.5 g/min)
Trial: 18369092
Drug: High-Fructose (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Fructose (0.7 g/min)
Trial: 18369092
Drug: No-Fructose (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-Fructose (0.0 g/min)
Trial: 15787663
Drug: Pioglitazone up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone up to 45 mg once daily
Trial: 15787663
Drug: Gliclazide up
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide up to 160 mg two times daily
Trial: 2013140
Drug: Early hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early hospital discharge on day 4 after aggressive interventional therapy
Trial: 25058803
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg methylprednisolone
Trial: 25311285
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET), 50-minute session
Trial: 15735106
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplement
Trial: 15735106
Drug: Daily multiple
RxNorm normalized name: Daily Multiple Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multiple micronutrient supplement
Trial: 15735106
Drug: Weekly multiple
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple micronutrient supplement with daily placebo
Trial: 15735106
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo supplement
Trial: 12898888
Drug: Basic dental
RxNorm normalized name: Basic Dental Emergency Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic dental care interventions focusing on prophylactics, education, and treatment
Trial: 29684999
Drug: Nano copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano copper (100 mg/kg/day)
Trial: 29684999
Drug: Copper sulfate
RxNorm normalized name: copper sulfate
DrugBank: Copper (DB09130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Copper sulfate (CuSO4) (50, 100, and 200 mg/kg/day)
Trial: 20681336
Drug: Progressive Self‐focus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Self‐focus Meditation (weekly 1‐hr. training sessions for 5 weeks)
Trial: 19026808
Drug: Esmolol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol as first-line antihypertensive medication in the operating room
Trial: 19026808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of esmolol and sodium nitroprusside (Nipride)
Trial: 19026808
Drug: Antihypertensive medications
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications at discharge
Trial: 1474178
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg adinazolam mesylate sustained release tablet
Trial: 1474178
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg immediate release tablet
Trial: 1474178
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intravenous adinazolam mesylate
Trial: 6096154
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg/day)
Trial: 29894287
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg before PCI)
Trial: 29894287
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg before PCI)
Trial: 25157768
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg plus carboplatin/paclitaxel (Arm A)
Trial: 18853833
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel (AG)
Trial: 15837412
Drug: Whole-body low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Whole-body low-dose multidetector row-CT (MDCT)
Trial: 9888625
Drug: Triazolam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.75 mg
Trial: 2507667
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg p.o. plus metoprolol 50 mg p.o.
Trial: 2507667
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg p.o. plus i.m. scopolamine 0.006 mg/kg and morphine 0.2 mg/kg
Trial: 320090
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no hormonal treatment)
Trial: 27500908
Drug: Internal Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Family Systems (IFS) therapy
Trial: 27500908
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (CBT or IPT)
Trial: 25440273
Drug: Methylprednisolone at
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone at anesthesia induction (30 mg/kg IV)
Trial: 25440273
Drug: Methylprednisolone by
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone by CPB prime (30 mg/kg)
Trial: 19304555
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release formulation of tramadol hydrochloride (TRH) based on osmotic technology
Trial: 19304555
Drug: Commercial TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial TRH tablets (control)
Trial: 19304555
Drug: Optimized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized formulation (batch IVB)
Trial: 11575344
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg ml(-1)
Trial: 11575344
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml(-1)
Trial: 3578927
Drug: Anti-H1 antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H1 antihistamines
Trial: 3578927
Drug: Oral cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cromolyn
Trial: 3578927
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of H1 and H2 anti-histamine drugs
Trial: 31982288
Drug: Zonisamide 50
RxNorm normalized name: zonisamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 50 mg/day
Trial: 29617585
Drug: Talc slurry
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc slurry (4 g) administered through indwelling pleural catheter
Trial: 29617585
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered through indwelling pleural catheter
Trial: 26891133
Drug: Caffeine 500
RxNorm normalized name: aspirin-caffeine 500 mg-32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 500 (400 mg caffeine with 500 mL water)
Trial: 26891133
Drug: Water 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 1500 (1500 mL water)
Trial: 26891133
Drug: Water 500
RxNorm normalized name: Water 500 mL in 500 mL PARENTERAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 500 (500 mL water)
Trial: 1563810
Drug: Pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (400 mg b.i.d.)
Trial: 1563810
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g t.i.d.)
Trial: 29858625
Drug: Soluble green/roasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble green/roasted coffee (6 g/day for 8 weeks)
Trial: 28807576
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 10 mL kg−1 (G10)
Trial: 28807576
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 12 mL kg−1 (G12)
Trial: 28807576
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 15 mL kg−1 (G15)
Trial: 26044075
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (1000 mg calcium carbonate with 400 IU vitamin D daily)
Trial: 20974015
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 administered for 30 days in humans
Trial: 16203271
Drug: Capecitabine/docetaxel combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine/docetaxel combination therapy
Trial: 2949057
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sertraline
Trial: 2949057
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sertraline
Trial: 2949057
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sertraline
Trial: 506742
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zimelidine
Trial: 30037660
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 25% albumin BID for three days
Trial: 27067532
Drug: Conventional calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional calcineurin inhibitor (CNI) therapy
Trial: 25060610
Drug: PRN injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN injections of 0.5 mg ranibizumab
Trial: 25060610
Drug: Monthly injections
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injections of 0.5 mg ranibizumab
Trial: 25060610
Drug: Non-randomized subjects
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomized subjects receiving monthly injections
Trial: 16504579
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg/day titrated to 50 mg/day